Trials / Completed
CompletedNCT03343652
A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's Lymphoma
A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of Nivolumab and Bendamustine Combination (NB) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- St. Petersburg State Pavlov Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A clinical study of safety and efficacy of treatment with Nivolumab and Bendamustine (NB) in patients with relapsed/refractory Hodgkin's lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab | 3 mg/kg IV infusion on day 1,14 up to 3 cycles |
| DRUG | Bendamustine Hydrochloride | 90 mg/kg IV infusion on day 1 up to 3 cycles |
Timeline
- Start date
- 2017-05-27
- Primary completion
- 2019-03-27
- Completion
- 2020-03-27
- First posted
- 2017-11-17
- Last updated
- 2020-05-28
Locations
1 site across 1 country: Russia
Source: ClinicalTrials.gov record NCT03343652. Inclusion in this directory is not an endorsement.